Latest news with #VTE
Zawya
2 days ago
- Business
- Zawya
Sky Medical Technology announces geko device adoption in Dubai hospitals
Dubai, UAE June 3rd 2025: Global medical device manufacturer Sky Medical Technology (Sky), parent company of Firstkind Ltd, today announced Dubai-based Genesis Healthcare, Dubai London Hospital and Mediclinic Parkview Hospital have adopted Sky Medical's innovative geko® device to accelerate chronic wound healing (leg ulcers), prevent and treat lower limb oedema (swelling) and to prevent venous thromboembolism (VTE - blood clots) in medically ill and immobile patients. The size of a small wrist-watch, the geko device is a wearable neuromuscular electrostimulator that is applied to the surface of the skin just below the knee. It delivers a gentle electrical pulse, once per second, to the common peroneal nerve, activating the calf and foot muscle pumps, increasing venous, arterial, and microcirculatory blood flow at a rate equal to 60%1 of walking, replicating the effects of exercise without a patient having to move. Commenting on the adoption of the geko device, Dr Ibrahim Riza, Consultant Vascular and Endovascular Surgeon, said: 'The geko device has been a game-changer in my practice. External compression, multi-layer bandaging, and drugs are the current standard of care for increasing blood circulation, but they do not work for all conditions. External compression and bandaging therapies can be complex to apply and uncomfortable to wear, leading to poor patient compliance, and drugs can carry an unpredictable bleed risk. The geko device overcomes these challenges and is uniquely positioned to address significant unmet needs when drug and current compression devices are impractical or contraindicated. As well as chronic wound healing and post-stroke VTE prevention, the geko device is highly effective in addressing lymphedema and maternity and travel-related oedema.' 'One of its biggest advantages is ease of use. The geko device is lightweight, silent, and completely non-invasive. Patients can wear it while sitting, lying down, and moving around, making it ideal for immobile patients and for those who are active in managing their recovery following surgery. By offering my patients the geko device, I provide them with a safe, comfortable, and effective way to support their vascular health, without the need for drugs or bulky equipment.' Commenting on behalf of Sky Medical Technology, CEO and Founder Bernard Ross: 'I am delighted that Dr Ibrahim Riza and his clinical team are benefiting from the geko device, which provides an effective and non-invasive way to manage vascular health and enhance recovery. We are proud to be partnered with hospitals and clinicians in Dubai who share our vision for advanced therapies that can deliver better patient outcomes and healthcare system savings.' About the geko device The patented geko device is a NICE-approved (MTG19), FDA-cleared, wearable neuromuscular electrostimulor. The size of a wristwatch and worn at the knee, the geko device gently stimulates the common peroneal nerve, activating the calf and foot muscle pumps, resulting in increased blood flow in the deep veins of the calf 2- at a rate equal to 60%1 of walking without a patient having to move. The blood flow volume and velocity increase prevents blood pooling and clotting, treats and prevents trauma-based and post-operative oedema, and in chronic wound care improves microcirculatory blood flow, delivering oxygenated blood to the wound bed to promote wound healing: About Firstkind and Sky Medical Technology Ltd Sky Medical Technology, the parent of Firstkind Ltd, is a UK-based medical devices company. Through its innovative mechanism of neuromuscular electrostimulation, Sky has developed a non-invasive, ground-breaking technology platform, OnPulse®, embedded in its industry-leading brand, the geko device. Sky's products are tailored to different medical application areas, selling through strategic partnerships or distributors in each major clinical area. Clinical areas of focus include life-threatening blood clots, complications related to swelling after surgery, and vascular conditions related to wound healing. The goal in each pathway is to partner with healthcare professionals to improve clinical outcomes and patient care whilst saving health system resources. About the Dubai hospitals Genesis Healthcare excels in advanced diagnostics and personalized care, making it a top choice for comprehensive wellness. Dubai London Hospital is known for its British-standard medical expertise, offering premium care across multiple specialties. Mediclinic Parkview Hospital stands out for its state-of-the-art technology, international medical staff, and patient-centric approach. Together, these hospitals represent the best of Dubai's healthcare sector, blending innovation, quality, and compassionate service to meet diverse patient needs in a world-class medical environment. About Abu Dhabi International Medical Services (ADI) Abu Dhabi International Medical Services (ADI) is a leading healthcare solutions provider in the UAE. As the exclusive distributor of the geko device from Firstkind, ADI brings advanced technology and expert support to enhance patient care across the region. Media contact Jargon Group
Trade Arabia
3 days ago
- Business
- Trade Arabia
Dubai hospitals to use geko device for patients
Dubai-based Genesis Healthcare, Dubai London Hospital and Mediclinic Parkview Hospital have adopted Sky Medical's innovative geko device to accelerate chronic wound healing (leg ulcers), prevent and treat lower limb oedema (swelling) and to prevent venous thromboembolism (VTE - blood clots) in medically ill and immobile patients. The size of a small wrist-watch, the geko device is a wearable neuromuscular electrostimulator that is applied to the surface of the skin just below the knee. It delivers a gentle electrical pulse, once per second, to the common peroneal nerve, activating the calf and foot muscle pumps, increasing venous, arterial, and microcirculatory blood flow at a rate equal to 60% of walking, replicating the effects of exercise without a patient having to move, said global medical device manufacturer Sky Medical Technology. Dr Ibrahim Riza, Consultant Vascular and Endovascular Surgeon, said: 'The geko device has been a game-changer in my practice. External compression, multi-layer bandaging, and drugs are the current standard of care for increasing blood circulation, but they do not work for all conditions. External compression and bandaging therapies can be complex to apply and uncomfortable to wear, leading to poor patient compliance, and drugs can carry an unpredictable bleed risk. The geko device overcomes these challenges and is uniquely positioned to address significant unmet needs when drug and current compression devices are impractical or contraindicated. As well as chronic wound healing and post-stroke VTE prevention, the geko device is highly effective in addressing lymphedema and maternity and travel-related oedema. 'One of its biggest advantages is ease of use. The geko device is lightweight, silent, and completely non-invasive. Patients can wear it while sitting, lying down, and moving around, making it ideal for immobile patients and for those who are active in managing their recovery following surgery. By offering my patients the geko device, I provide them with a safe, comfortable, and effective way to support their vascular health, without the need for drugs or bulky equipment.' Sky Medical Technology CEO and Founder Bernard Ross: 'I am delighted that Dr Ibrahim Riza and his clinical team are benefiting from the geko device, which provides an effective and non-invasive way to manage vascular health and enhance recovery. We are proud to be partnered with hospitals and clinicians in Dubai who share our vision for advanced therapies that can deliver better patient outcomes and healthcare system savings.'
Medscape
15-05-2025
- Health
- Medscape
Seeking a Perfect Risk-Benefit Balance in Treating VTE
At the dawn of the 21st century, venous thromboembolism (VTE) treatment remained in the dark ages. Backed by an MD and a legacy of paternalistic practice, we convinced patients to do what now seems unthinkable. Unfractionated heparin may come from pigs and cattle, but we infused it like snake oil. Patients spent 5 (or more) days in the hospital chasing partial thromboplastin times and enduring stops and starts with repeated blood draws. Finally, we discharged them on the only drug awful enough to require an eponymous nursing position and clinic. Our approach to balancing risk-benefit was equally primitive. Patients diagnosed with their first VTE were given the proverbial 'trial of life.' They generally received 3-6 months of anticoagulation before being advised to stop, with guidance as blithe as it was vague: 'If you feel short of breath, go to the emergency room.' It mattered not whether their initial clot was a pulmonary embolism or a deep vein thrombosis. Or whether there was comorbid cardiopulmonary disease. If they had a second VTE, assuming they survived it, the initial treatment regimen (including the hospitalization) was repeated. By 2008, our guidelines had incorporated data showing that for unprovoked events, fixed courses of anticoagulation provided less mitigation than delay. This pushed risk-benefit analysis to the forefront of all things VTE. Physicians, and patients, were forced to balance VTE recurrence with bleeding risk and decide whether to stop treatment after 3 months or continue it indefinitely. Shortly thereafter, the novel blood thinners hit the market, making indefinite anticoagulation slightly more palatable. Meanwhile, the field continued to refine risk calculations. D-dimer testing had its moment in the sun before being knocked down a notch by the 2016 CHEST VTE guidelines. Lower-extremity ultrasound also helped, but it wasn't quite clear where and how it fit into overall risk after accounting for other factors. Both have given way to more complicated models that perform well in particular situations. There are even online risk calculators to help battle the viscous time scarcity epidemic afflicting all 21st century medicine clinics. The latest breakthrough reduces bleeding more than VTE recurrence risk. In 2013, the AMPLIFY-EXT trial showed that after 6 months of full-dose treatment, a half dose of apixaban reduced bleeding without increasing recurrence risk. Not to be outdone, these findings were replicated using rivaroxaban in the EINSTEIN CHOICE study. Taken together, AMPLIFY-EXT and EINSTEIN CHOICE provide strong evidence that for those with a first episode of VTE with clinical equipoise (defined as uncertainty as to whether risk-benefit favored continued treatment) after 6 months of full-dose anticoagulation, reduced doses of apixaban or rivaroxaban are excellent options. The most recent iteration of the CHEST VTE Treatment Guidelines endorses this practice. Because AMPLIFY-EXT and EINSTEIN CHOICE had the "clinical equipoise" proviso in their inclusion criteria, cancer patients were largely excluded. There's generally not equipoise for them; VTE recurrence risk is expected to remain indefinitely high, requiring indefinite protection. So, the practice of reduced dosing could not be generalized to cancer-related VTE — until now. The API-CAT investigators very recently published reduced-dose data for cancer patients. Turns out, it works! As the accompanying editorial points out, advances in cancer treatment have led to increased survival times. Longer survival with active cancer translates to more cancer-related VTE. The API-CAT data are a critical addition to the literature. The sooner they're incorporated, the better.
Associated Press
15-05-2025
- Health
- Associated Press
National Blood Clot Alliance (NBCA) Designates Two AdventHealth Hospitals as Centers of Excellence for VTE Care
Recognition Highlights AdventHealth's Commitment to Exceptional Care in Blood Clot Prevention, Diagnosis, and Treatment 'I am immensely proud of the work we have done in VTE treatment and intervention, and very grateful for the recognition that this COE represents.'— Dr. Arkadiy Kheyfits, AdventHealth Palm Coast and Palm Coast Parkway PALM COAST, FL, UNITED STATES, May 15, 2025 / / -- The National Blood Clot Alliance (NBCA) is proud to announce the designation of AdventHealth Palm Coast and AdventHealth Palm Coast Parkway as NBCA Venous Thromboembolism (VTE) Centers of Excellence™. These hospitals are the first in the AdventHealth system and the first in Northeast Florida to earn this prestigious recognition for their commitment to delivering exceptional, patient-centered care in the prevention, diagnosis, and treatment of blood clots. Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), remains a significant public health concern in the United States. According to the Centers for Disease Control and Prevention (CDC), up to 900,000 people in the U.S. are affected by VTE each year, and as many as 100,000 die as a result. Despite these alarming numbers, VTE remains underdiagnosed and undertreated—highlighting the importance of comprehensive, multidisciplinary approaches to care. 'I am immensely proud of the work we have done in VTE treatment and intervention, and very grateful for the recognition that this COE represents' said Dr. Arkadiy Kheyfits, Interventional Radiologist at AdventHealth Palm Coast and Palm Coast Parkway.' I believe AdventHealth Palm Coast and Palm Coast Parkway are leaders in this space, and I am excited to continue improving our care and prevention pathways.' As NBCA VTE Centers of Excellence™, both AdventHealth Palm Coast campuses join a growing network of leading institutions recognized for advancing VTE care through clinical excellence, innovation, and a commitment to education and prevention. This expanding network includes distinguished centers such as Corewell Health West Butterworth Hospital in Grand Rapids, MI, and Ascension Sacred Heart Hospital in Pensacola, FL. 'NBCA VTE Centers of Excellence™ are setting a new standard in how we approach VTE—from acute management to long-term prevention,' said Erin VanDyke, PA-C, Vice President of the NBCA COE Program. 'The teams at AdventHealth Palm Coast and Palm Coast Parkway exemplify the mission of this program through their multidisciplinary collaboration, dedication to best practices, and focus on patient outcomes. We are proud to welcome them as the first designated Centers of Excellence in both the AdventHealth system and Northeast Florida.' The NBCA COE program aims to improve outcomes and save lives by partnering with institutions that embrace innovative, evidence-based, and patient-focused strategies to prevent and treat VTE. To learn more about the NBCA VTE Centers of Excellence™ program, visit About the National Blood Clot Alliance (NBCA) Established in 2003, the National Blood Clot Alliance (NBCA) is the nation's leading nonprofit, patient advocacy organization dedicated to advancing the prevention, early diagnosis, and treatment of life-threatening blood clots. Through a strategic focus on education, advocacy, and research, NBCA empowers patients and families, supports healthcare professionals, and drives national efforts to improve awareness, detection, and outcomes related to VTE. NBCA leads initiatives that strengthen the standard of care and foster innovation in VTE prevention and treatment across the United States. About AdventHealth AdventHealth is a connected network of care that helps people feel whole – body, mind and spirit. More than 100,000 team members across a national footprint provide whole-person care to nearly nine million people annually through more than 2,000 care sites that include hospitals, physician practices, ambulatory surgery centers, outpatient clinics, home health agencies, hospice centers, the AdventHealth app and more. Our wholistic approach to improving the health and prosperity of our communities is inspired by our mission to extend the healing ministry of Christ. For the latest news about AdventHealth, visit Tarin Patrikis National Blood Clot Alliance [email protected] Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
